Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Dr. Sara M. Tolaney discusses key takeaways from the DESTINY-Breast09 trial that sufferers with HER2+ superior or metastatic breast most cancers ought to...
Rybrevant plus chemotherapy improved response and delayed illness development for sufferers with EGFR-mutated lung most cancers after Tagrisso remedy.Amongst sufferers with EGFR-mutated non–small...
